Alzheimer's Disease Clinical Trials in North Carolina

24 recruiting studies across 2 cities

Browse by City

All Trials in North Carolina

Phase

Trial	Phase	Sponsor	Dist.
[18F]PI-2620 Phase 3 Histopathological Study	Phase 3	Lantheus Biosciences Ltd.	<1 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease	Phase 2	Celgene	<1 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease	Phase 2	Intra-Cellular Therapies, Inc.	<1 mi
Late Onset Alzheimer's Disease	—	Columbia University	<1 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia	Phase 2	Intra-Cellular Therapies, Inc.	<1 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	10 mi
Open-label Extension Study in Participants With Early Alzheimer's Disease	Phase 2	GlaxoSmithKline	10 mi
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	10 mi
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)	Phase 1/2	AC Immune SA	10 mi
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)	Phase 2	Alzheimer's Disease Cooperative Study (ADCS)	10 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)	Phase 2	Merck Sharp & Dohme LLC	10 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease	Phase 3	Bristol-Myers Squibb	10 mi
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism	Phase 2	Duke University	21 mi
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease	Phase 1	Eli Lilly and Company	21 mi
Preventing Alzheimer's With Cognitive Training	Phase 3	University of South Florida	21 mi
Olfactory Biopsies	N/A	Duke University	21 mi
ADRC Clinical Cohort (Alzheimer's Disease)	—	Duke University	21 mi
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)	Phase 1	Eli Lilly and Company	21 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	Phase 3	Eidos Therapeutics, a BridgeBio company	21 mi
Retinal Imaging in Neurodegenerative Disease	—	Duke University	21 mi
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease	Phase 2	Novartis Pharmaceuticals	25 mi
Connect-Home: Alzheimer's Disease and Related Dementias	N/A	University of North Carolina, Chapel Hill	25 mi
Improving PCP Advance Care Planning for People With ADRD	N/A	University of Pittsburgh	25 mi
Physical Activity and Community EmPOWERment Project	N/A	University of North Carolina, Chapel Hill	25 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.